Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-COVID paediatric dysautonomia: never the heart, always the brain-myth or maxim?

Cardiology in the young·2026
Same author

How Close Are We? Neuropsychologic Assessment in New-Onset Pediatric Epilepsy.

Pediatric neurology·2025
Same author

Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis.

Neurology·2025
Same author

Neurofibromatosis type 2-related schwannomatosis - An update.

Seminars in pediatric neurology·2024
Same author

Isolated Psychiatric Symptoms in Children With Anti-N-Methyl-d Aspartate Receptor Encephalitis.

Pediatric neurology·2024
Same author

MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis.

Neurology(R) neuroimmunology & neuroinflammation·2023

Related Experiment Video

Updated: Jun 6, 2025

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
05:44

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development

Published on: May 17, 2024

515

Neurofibromatosis type 1 - an update.

Manikum Moodley1, Karla Robles Lopez1

  • 1Pediatric Neuroscience at Dell Children's Medical CenterThe University of Texas at Austin Dell Medical School, USA.

Seminars in Pediatric Neurology
|December 2, 2024
PubMed
Summary

Neurofibromatosis type 1 (NF1) is a common genetic disorder with varied symptoms like skin changes and tumors. While a cure is unavailable, new treatments target the RAS/MAPK pathway.

Keywords:
Café-au-lait maculesChild neurologyLisch nodulesNF1NeurofibromasNeurofibromatosisOptic gliomaPediatric neurology

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 6, 2025

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
05:44

Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development

Published on: May 17, 2024

515
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

Area of Science:

  • Genetics
  • Dermatology
  • Oncology

Background:

  • Neurofibromatosis type 1 (NF1) is a prevalent autosomal dominant genetic condition.
  • NF1 presents with diverse clinical manifestations, including café-au-lait macules, neurofibromas, and Lisch nodules.
  • The condition exhibits complete penetrance but significant variability in disease expression.

Purpose of the Study:

  • To summarize the key features and current understanding of Neurofibromatosis type 1.
  • To highlight the variability in clinical presentation and disease onset.
  • To introduce emerging therapeutic strategies for NF1.

Main Methods:

  • Literature review of Neurofibromatosis type 1.
  • Analysis of clinical characteristics and genetic inheritance patterns.
  • Overview of current and developing treatment modalities.

Main Results:

  • NF1 is characterized by a spectrum of physical findings, with some appearing in early childhood and others later in life.
  • Café-au-lait macules, bony abnormalities, and optic pathway gliomas are common early signs.
  • Variable expressivity is a hallmark of NF1, impacting diagnosis and management.

Conclusions:

  • Neurofibromatosis type 1 is a complex genetic disorder requiring lifelong monitoring.
  • Management of NF1 involves addressing diverse symptoms and potential complications.
  • Targeting the RAS/MAPK signaling pathway represents a promising therapeutic avenue for NF1.